United States
Germany
Japan
United Kingdom
China
Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Antibodies
Anti-Siglec-2 / CD22 Reference Antibody (NCI m972)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-Siglec-2 / CD22 Reference Antibody (NCI m971)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Rat, Cynomolgus |
Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-MMAE)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-Siglec-2 / CD22 Reference Antibody (moxetumomab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
Anti-Siglec-2 / CD22 Reference Antibody (epratuzumab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
